Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Arnel Pallera (NPI 1083643845)

Field	Value
Entity Type	Individual
Organization	Arnel Pallera
Address	7945 Wolf River Blvd
City	Germantown
State	TN
ZIP	38138
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 2, 2006

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

This provider is functionally an oncology infusion practice: the largest Medicare revenue contributors are high-cost monoclonal antibody and checkpoint inhibitor injections (J9271, J9299, J9144), together accounting for 67.4% of total Medicare revenue. The code descriptions (pembrolizumab, nivolumab, daratumumab) and substantial claim counts (e.g., J9271: 21.2K claims, $911.6K revenue) point to routine in-clinic administration of immunotherapy and targeted agents as the core service line.

Revenue is heavily concentrated in a few drug administration codes: J9271 alone represents $911.6K (44.1% of Medicare revenue), while J9299 ($247K, 12.0%) and J9144 ($233.1K, 11.3%) are the next largest contributors. The precomputed metric that the top 3 Medicare codes account for 67.4% of Medicare revenue underscores that a small set of infusion drugs drive the bulk of this provider’s Medicare billing.

This provider’s payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $2.2M and there is no Medicaid billing on file. The absence of Medicaid activity suggests limited participation in state programs or a Medicare-heavy panel, which is an important consideration for payers modeling network adequacy or shifting volume assumptions.

Competitive standing is mixed across codes: for high-revenue oncology drugs this provider is a modest national participant (J9271 ranks #340 of 1841, 81th percentile; J9299 ranks #335 of 505, 34th percentile; J9144 ranks #408 of 615, 32th percentile), indicating typical national volumes for these agents rather than market dominance. By contrast, the provider is a clear outlier on outpatient evaluation-and-management, with 99214 ranking #6539 of 479517 (99th percentile; extreme outlier), implying unusually high volume of moderate-complexity office visits relative to peers.

Operationally the code mix shows a full-spectrum oncology practice: beyond checkpoint inhibitors the provider bills supportive and adjunctive oncology services such as denosumab (J0897: 6.1K claims, $110.2K revenue), pegfilgrastim (J2506: 216 claims, $17.9K), chemotherapy administration codes (96413: 376 claims, $35.7K), and EOM enhanced-service payments (M0010: 310 claims, $21.7K). High-volume lab and point-of-care testing codes (80048, 80076, 85025, 36415 all in high national percentiles) further support a clinic that handles diagnostics and treatment monitoring on site.

Statistical outliers and percentile signals refine competitive interpretation: 99214 is labeled an "extreme outlier, far above typical national volume for this code," while M0010 ranks #15 of 544 (97th percentile) showing strong participation in the Enhanced Oncology Model. Several common infusion and lab codes fall in typical national ranges (noted percentiles in the 20s–80s), but codes with very low percentiles such as J1439 (4th percentile) indicate minimal contribution or different sourcing for specific lower-paid products.

Tenure and provider stability are notable: the NPI was enumerated on 2006-07-02 (~20 years ago), signaling a long-established billing history that supports continuity in referral patterns and recorded Medicare volume. This longevity, paired with concentrated high-revenue drug billing, suggests an established oncology practice rather than a recent entrant.

Payer and coding implications for partners: because a small set of infusion drugs produce most Medicare revenue and there is no Medicaid activity, payers should treat this provider as a Medicare-centric oncology infusion site with predictable drug-administration revenue streams. Network or contract negotiations should focus on inpatient/clinic infusion capacity, EOM participation (M0010 high rank), and unusually high office visit volume (99214 extreme outlier), which together drive utilization and cost exposure.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

91 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	21,200	$40	$911.6K
J9299	Injection, nivolumab, 1 mg	10,740	$20	$247K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,300	$40	$233.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,240	$90	$110.2K
J0897	Injection, denosumab, 1 mg	6,120	$20	$110.2K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,170	$30	$73.8K
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	1,470	$40	$51.5K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	1,830	$20	$42.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	380	$100	$35.7K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	13,100	$1	$26.2K

Showing 1–10 of 91

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 91 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Arnel Pallera — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

91 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	14	50	17,400	$40	$776.1K
J9299	16	20	21,010	$20	$487.5K
J9144	17	20	10,080	$40	$466.3K
J1569	20	30	3,030	$40	$175.2K
J1437	21	20	3,700	$20	$86.3K
J0897	55	240	2,940	$20	$85K
Q5107	14	20	2,990	$20	$77.6K
Q5123	10	10	1,960	$40	$70.9K
J0881	56	70	19,050	$1	$54.4K
88185	13	30	690	$20	$51.2K

Showing 1–10 of 91

Related Providers

Other providers that share a Tax Identification Number (TIN) with Arnel Pallera, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The West Clinic P.C.	TN	Specialist	$0	$16M
David Portnoy	TN	Hematology & Oncology Physician	$6.5M	$0
Kurt Tauer	TN	Medical Oncology Physician	$3.9M	$0
Gang Tian	TN	Hematology & Oncology Physician	$3.8M	$0
Jason Chandler	TN	Medical Oncology Physician	$3.8M	$0
Syed Sameer Nasir	TN	Hematology & Oncology Physician	$3.5M	$0
Ramakrishna Battini	TN	Hematology & Oncology Physician	$3.3M	$0
Eric Wiedower	TN	Hematology & Oncology Physician	$2.9M	$0
Bradley Somer	TN	Hematology & Oncology Physician	$2.8M	$0
Robert Johnson	TN	Hematology & Oncology Physician	$2.8M	$0

Nearby Providers

Other providers in the same ZIP code as Arnel Pallera, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Byram Healthcare Centers, Inc.	TN	Durable Medical Equipment & Medical Supplies	$0	$44.3M
Campbell Clinic, PC	TN	Orthopaedic Surgery Physician	$0	$28M
Poplar Avenue Clinic PLLC	TN	Gynecologic Oncology Physician	$0	$9.7M
Diagnostic Ultrasound Consultants	TN	Diagnostic Radiology Physician	$0	$8.5M
Mid-south Imaging & Therapeutics, P.A.	TN	Diagnostic Radiology Physician	$0	$8.2M
Stephen Huddleston	TN	Retina Specialist (Ophthalmology) Physician	$5.7M	$0
Stern Cardiovascular Foundation, Inc	TN	Cardiovascular Disease Physician	$0	$4.7M
G I Diagnostic And Therapeutic Center LLC	TN	Endoscopy Clinic/Center	$4.2M	$8.6K
Memphis Neurology PLLC	TN	Neurology Physician	$0	$3.9M
Raza Hashmi	TN	Rheumatology Physician	$3.9M	$0

Arnel Pallera — Billing Profile & Reimbursement Data

Sign up for Arnel Pallera — Billing Profile & Reimbursement Data policy alerts

Arnel Pallera — Billing Profile & Reimbursement Data

Sign up for Arnel Pallera — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References